At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 194 enrolled
Drug / intervention
Nivolumab +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of Nivolumab (BMS-936558) Plus Sunitinib, Pazopanib or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma
In Brief
A Phase 1 clinical trial evaluating Nivolumab, Pazopanib, and 2 other interventions for Renal Cell Carcinoma and Clear-cell Metastatic Renal Cell Carcinoma. Completed, enrolled 194 participants across 14 sites in 2 countries.
Detailed Summary
The purpose is to determine the safety, effectiveness and best dose to use when giving Nivolumab in combination with Sunitinib, Pazopanib, or Ipilimumab for the treatment of metastatic renal cell carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
CollaboratorsOno Pharmaceutical Co., Ltd.
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartFeb 2012
Primary CompletionFeb 2016
Study CompletionJun 2021
TodayJul 2026
First PostedNov 16, 2011
Enrollment StartFeb 9, 2012
Primary CompletionFeb 2, 2016
Study CompletionJun 3, 2021
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 14.6 years ago
Interventions
Nivolumabbiological
Pazopanibbiological
Sunitinibdrug
Ipilimumabbiological